Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shark cartilage

This article was originally published in The Tan Sheet

Executive Summary

Phase II safety studies of shark cartilage-derived supplement Neovastat provided enough evidence to initiate Phase III efficacy investigations, according to materials presented at the annual meeting of the American Association for Cancer Research. In one of four clinical oncology studies already completed, a subgroup of 47 people with "unresectable non-small cell lung cancer" administered the product for over six months "indicated a significant increase of survival time" (6.15 months vs. 4.17 months) and a 2.5-fold decrease in risk of death after receiving 2.63 ml/kg/day of Neovastat, Gerald Batist, MD, Institut Gustave Roussy, Villejuif, France, et al. state. The results have led to initiation of two new studies: one in 750 lung cancer patients and another in a group of 280 subjects with metastatic renal cell carcinoma. Saint Foy, Quebec-based Aeterna, which manufactures Neovastat, funded the study
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS092411

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel